Biolik biopharmaceutical company is located in Kharkov, Ukraine. Biolik was established in 1898 in cooperation with academic Ilya Metchnikov, the Nobel Prize winner in the theory of phagocytosis, 1908. Biolik currently employs a staff of 750 employees, including more than 150 of highly qualified engineers and technical personnel, 25 microbiologists, 6 virologists, 12 chemists, 5 veterinarian physicians, 10 technologists, 5 pharmacologists, 15 technical engineers, 3 physicians-epidemiologists and 7 PhDs. The company continues to uphold its traditions of excellence in manufacturing of vaccines, biologic medications, sera and antisera, and injectable final dosage forms. Biolik possesses a unique know-how in development of liposomal drug preparations including liposomal doxorubicin (Lipodox™), liposomal quercetin ( Lipoflavon™), and metallorganic compound in liposomes ( Lioliv™). Liposomal taxanes and cisplatin are currently under development.

Biolik is the only manufacturer of vaccines for prophylaxis of infectious diseases in Ukraine. The company has started manufacturing of DTP vaccine and DT, DTM, D-M and T antitoxins since 1996. It has developed a full-cycle manufacturing of all vaccine components: Purified concentrated Diphtheria antitoxin, Purified concentrated Tetanus antitoxin, Pertussis suspension. Biolik is currently developing International cooperation with the major world producers of vaccine APIs in order to develop full range of injectable vaccine dosage forms for Ukraine market. We are actively working toward the development of production of alpha and beta interferon, G-CSF and GM-CSF, erythropoietin, as well as other biologic medications.

Recent acquisition of Biolik by Solux Corporation brought together the unique capabilities of Biolik, as a formidable manufacturer of the injectable dosage forms, with the outstanding selection of APIs produced by Synbias Pharma. This acquisition makes our company exceptionally competitive in all spheres of pharmaceutical manufacturing with strong expectations for growth of opportunities in the future